The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Caught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Self-citationInsulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., & Comoglio, P. M. (1994) · Cell · doi:10.1016/0092-8674(94)90318-2 · Cited by 991
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
Fundamental Concepts of the Angiogenic Process
Folkman, J. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479465 · Cited by 666
Emerging Multipotent Aspects of Hepatocyte Growth Factor
Matsumoto, K., & Nakamura, T. (1996) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021283 · Cited by 660
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Self-citationRegulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Self-citationBAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C
Marais, R., Light, Y., Mason, C., Paterson, H., Olson, M. F., & Marshall, C. J. (1998) · Science · doi:10.1126/science.280.5360.109 · Cited by 441
Self-citationKaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Self-citationRhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
Simonetti, R. G., Liberati, A., Angiolini, C., & Pagliaro, L. (1997) · Annals of Oncology · doi:10.1023/a:1008285123736 · Cited by 380
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J.-F. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 372
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
Burtrum, D. B., Zhu, Z., Lu, D., Anderson, D. M., Prewett, M. C., PEREIRA, D. S., Bassi, R., Abdullah, R., Hooper, A. T., Koo, H., et al. (2003) · PubMed · Cited by 352
Wong, C. M., Fan, S. T., & Ng, I. O. L. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r · Cited by 348
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois‐Mouthon, C., Rey, C., Clergue, F., Poupon, R., Barbu, V., & Rosmorduc, O. (2005) · Hepatology · doi:10.1002/hep.20538 · Cited by 340
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A., Glover, K., Davila, M., & Abbruzzese, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
El-Assal, O. N., Yamanoi, A., Soda, Y., Yamaguchi, M., Igarashi, M., Yamamoto, A., Nabika, T., & Nagasue, N. (1998) · Hepatology · doi:10.1002/hep.510270613 · Cited by 326
Desbois-Mouthon, C., Cadoret, A., Blivet-Van Eggelpoël, M.-J., Bertrand, F., Cherqui, G., Perret, C., & Capeau, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204064 · Cited by 321
Raf kinases: Function, regulation and role in human cancer
Leicht, D. T., Balan, V., Kaplun, A., Singh-Gupta, V., Kaplun, L., Dobson, M., & Tzivion, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.001 · Cited by 317
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H.-J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
Hu, T., Huang, C., Lin, P., Chang, H., Ger, L., Lin, Y., Changchien, C., Lee, C., & Tai, M. (2003) · Cancer · doi:10.1002/cncr.11266 · Cited by 277
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Self-citationAnalysis of the transcriptional program induced by Raf in epithelial cells
Schulze, A., Lehmann, K., Jefferies, H. B. J., McMahon, M., & Downward, J. (2001) · Genes & Development · doi:10.1101/gad.191101 · Cited by 259
Kneteman, N. M., Oberholzer, J., Al Saghier, M., Meeberg, G. A., Blitz, M., Ma, M. M., Wong, W. W. S., Gutfreund, K., Mason, A. L., Jewell, L. D., et al. (2004) · Liver Transplantation · doi:10.1002/lt.20237 · Cited by 256
Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., Chen, Q., Ho, S.-Y., Li, L., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3329 · Cited by 252
Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Zhu, A. X., Stuart, K., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark, J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K., et al. (2007) · Cancer · doi:10.1002/cncr.22829 · Cited by 246
Self-citationMolecular pathogenesis of human hepatocellular carcinoma
Wang, X. W., Hussain, S. P., Huo, T.-I., Wu, C.-G., Forgues, M., Hofseth, L. J., Brechot, C., & Harris, C. C. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00253-6 · Cited by 246
Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229
Poon, R. T. P., Ho, J. W. Y., Tong, C. S. W., Lau, C., Ng, I. O. L., & Fan, S.-T. (2004) · British Journal of Surgery · doi:10.1002/bjs.4594 · Cited by 228
Semela, D., Piguet, A.-C., Kolev, M., Schmitter, K., Hlushchuk, R., Djonov, V., Stoupis, C., & Dufour, J.-F. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.021 · Cited by 225
Nakanishi, K., Sakamoto, M., Yamasaki, S., Todo, S., & Hirohashi, S. (2005) · Cancer · doi:10.1002/cncr.20774 · Cited by 222
Chao, Y., Li, C.-P., Chau, G.-Y., Chen, C.-P., King, K.-L., Lui, W.-Y., Yen, S.-H., Chang, F.-Y., Chan, W.-K., & Lee, S.-D. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.10.002 · Cited by 209
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Albert, D. H., Tapang, P., Magoc, T. J., Pease, L. J., Reuter, D. R., Wei, R.-Q., Li, J., Guo, J., Bousquet, P. F., Ghoreishi-Haack, N. S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0410 · Cited by 207
Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M., Ullrich, A., & Bréchot, C. (1988) · PubMed · Cited by 193
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.029 · Cited by 191
Anzola, M. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00521.x · Cited by 191
Souza, A. T. D., Hankins, G. R., Washington, M. K., Fine, R. L., Orton, T. C., & Jirtle, R. L. (1995) · PubMed · Cited by 187
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Johnston, S. R. D., & Leary, A. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.7.985637 · Cited by 174
Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.024 · Cited by 173
Opportunities for Targeted Therapies in Hepatocellular Carcinoma
Thomas, M. B., & Abbruzzese, J. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1537 · Cited by 172
Yoshida, T., Hisamoto, T., Akiba, J., Koga, H., Nakamura, K., Tokunaga, Y., Hanada, S., Kumemura, H., Maeyama, M., Harada, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209635 · Cited by 169
Huether, A., Höpfner, M., Sutter, A. P., Schuppan, D., & Scherübl, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.040 · Cited by 167
Wu, J. D., Odman, A., Higgins, L. M., Haugk, K., Vessella, R., Ludwig, D. L., & Plymate, S. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1586 · Cited by 167
Ng, I. O. L., Poon, R. T. P., Lee, J. M. F., Fan, S. T., Ng, M., & Tso, W. K. (2001) · American Journal of Clinical Pathology · doi:10.1309/fxnl-qtn1-94fh-ab3a · Cited by 163
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Whittaker, S. R., Kirk, R., Hayward, R., Zambon, A., Virós, A., Cantariño, N., Affolter, A., Nourry, A., Niculescu‐Duvaz, D., Springer, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000758 · Cited by 158
Self-citationSieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J. M., Wrba, F., Wang, X., Gruber, D., Rasoul‐Rockenschaub, S., Peck‐Radosavljevic, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000252780.42104.95 · Cited by 154
Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
REGULATION OF PHOSPHOLIPASE C ISOZYMES BY RAS SUPERFAMILY GTPASES
Harden, T. K., & Sondek, J. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141223 · Cited by 138
Pang, R. W. C., Lee, T. K., Poon, R. T. P., Fan, S. T., Wong, K., Kwong, Y., & Tse, E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.12.030 · Cited by 137
Kiss, A., Wang, N. J., Xie, J. P., & Thorgeirsson, S. S. (1997) · PubMed · Cited by 135
Lierman, E., Folens, C., Stover, E. H., Mentens, N., Miegroet, H. V., Scheers, W., Boogaerts, M., Vandenberghe, P., Marynen, P., & Cools, J. (2006) · Blood · doi:10.1182/blood-2006-02-004457 · Cited by 132
Hsu, C., Yang, T.-S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L.-T., Chen, P.-J., Lin, Z.-Z., Chao, T.-Y., & Cheng, A.-L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605580 · Cited by 131
Molecular Mechanisms Involved in Macrophage Survival, Proliferation, Activation or Apoptosis
Xaus, J., Comalada, M., Valledor, A. F., Cardó, M., Herrero, C., Soler, C., Lloberas, J., & Celada, A. (2001) · Immunobiology · doi:10.1078/0171-2985-00091 · Cited by 129
Yeh, Y., Tsai, J., Chuang, L., Yeh, H.-W., Tsai, J., Florine, D. L., & Tam, J. P. (1987) · PubMed · Cited by 128
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
Zhu, A. X. (2007) · Cancer · doi:10.1002/cncr.23175 · Cited by 128
Self-citationExpression of the C– Met Protooncogene in Human Hepatocellular Carcinoma
Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., et al. (1994) · Hepatology · doi:10.1002/hep.1840200520 · Cited by 125
c-met mRNA overexpression in human hepatocellular carcinoma
Boix, L., Rosa, J. L., Ventura, F., Castells, A., Bruix, J., Rodés, J., & Bartrons, R. (1994) · Hepatology · doi:10.1002/hep.1840190115 · Cited by 124
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Ma, P. C., Schaefer, E., Christensen, J. G., & Salgia, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1708 · Cited by 124
Schirmacher, P., Held, W. A., Yang, D., et al. (1992) · PubMed · Cited by 123
Development of Hepatocellular Carcinoma in Iqgap2 -Deficient Mice Is IQGAP1 Dependent
Schmidt, V. A., Chiariello, C. S., Capilla, E., Miller, F. W., & Bahou, W. F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01090-07 · Cited by 121
Sananbenesi, F. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1188 · Cited by 114
Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Chen, Y., Law, P. C., & Loh, H. H. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/156801105774574649 · Cited by 113
Tavian, D., Petro, G. D., Benetti, A., Portolani, N., Giulini, S. M., & Barlati, S. (2000) · International Journal of Cancer · Cited by 110
Prognostic significance of HIF-2α/EPAS1 expression in hepatocellular carcinoma
Bangoura, G., Liu, Z.-S., Qian, Q., Jiang, C.-Q., Yang, G.-F., & Jing, S. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i23.3176 · Cited by 109
Höpfner, M., Huether, A., Sutter, A. P., Baradari, V., Schuppan, D., & Scherübl, H. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.006 · Cited by 106
O'Dwyer, P. J., Giantonio, B. J., Levy, D. E., Kauh, J. S. W., Fitzgerald, D. B., & Benson, A. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4143 · Cited by 106
Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H. J., Mendelson, D. S., Shannon, P., & Gordon, M. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3513 · Cited by 95
Feng, D. Y. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i1.33 · Cited by 91
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
Himmelsbach, K., Sauter, D., Baumert, T. F., Ludwig, L., Blum, H. E., & Hildt, E. (2009) · Gut · doi:10.1136/gut.2009.182212 · Cited by 87
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma
Schuierer, M. M., Bataille, F., Weiß, T. S., Hellerbrand, C., & Bosserhoff, A. (2006) · Oncology Reports · doi:10.3892/or.16.3.451 · Cited by 86
McKillop, I. H., Schmidt, C. M., Cahill, P. A., & Sitzmann, J. V. (1997) · Hepatology · doi:10.1002/hep.510260615 · Cited by 81
Zhou, J., Tang, Z., Fan, J., Wu, Z.-Q., Li, X., Liu, Y., Liu, F., Sun, H., & Ye, S. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050009 · Cited by 74
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients
Tanaka, Y., Kanai, F., Tada, M., Asaoka, Y., Guleng, B., Jazag, A., Ohta, M., Ikenoue, T., Tateishi, K., Obi, S., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209311 · Cited by 74
Ueda, S.-I., Basaki, Y., Yoshie, M., Ogawa, K., Sakisaka, S., Kuwano, M., & Ono, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3684 · Cited by 72
Review article: steatosis, the metabolic syndrome and cancer
Bugianesi, E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02594.x · Cited by 71
Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K. C., & Fisher, R. A. (2007) · Transplantation · doi:10.1097/01.tp.0000287596.91520.1a · Cited by 69
ASCO 2020 Gastrointestinal Cancers Symposium
Pinion, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30045-5 · Cited by 69
WATANABE, S., HORIE, Y., & Suzuki, A. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.09.026 · Cited by 67
Dhar, D. K., Naora, H., Yamanoi, A., et al. (2002) · PubMed · Cited by 61
Early molecular and genetic determinants of primary liver malignancy
Feitelson, M. A., Pan, J., & Lian, Z. (2004) · Surgical Clinics of North America · doi:10.1016/s0039-6109(03)00226-3 · Cited by 58
Shimamura, T., Saito, S., Morita, K., Kitamura, T., Morimoto, M., Kiba, T., Numata, K., Tanaka, K., & Sekihara, H. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02201.x · Cited by 58
Huynh, H. T., Chow, P. K. H., & Soo, K. C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0162 · Cited by 50
Lund, P., Schubert, D., Niketeghad, F., et al. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.018 · Cited by 47
Halaschek-Wiener, J., Wacheck, V., Kloog, Y., & Jansen, B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.003 · Cited by 45
Stöckl, L., Berting, A., Malkowski, B., Foerste, R., HOFSCHNEIDER, P. H., & Hildt, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206320 · Cited by 43
Management of hepatocellular cancer
Mulcahy, M. F. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0045-7 · Cited by 41
Emerging drugs for hepatocellular carcinoma
Roberts, L. R., & Gores, G. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.469 · Cited by 39
Koch, I., Baron, A., Roberts, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4134 · Cited by 38
Huether, A., Höpfner, M., Sutter, A. P., Baradari, V., Schuppan, D., & Scherübl, H. (2006) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v12.i32.5160 · Cited by 37
Krebsbach, P. H., Zhang, K., Malik, A. K., & Kurachi, K. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.292 · Cited by 35
Lian, Z., Liu, J., Wu, M., et al. (2007) · Hepatology · doi:10.1002/hep.21610 · Cited by 35
Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development
To, M. D., Pérez‐Losada, J., Mao, J., & Balmain, A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2039 · Cited by 24
Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells
Zhang, Y. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i25.3977 · Cited by 21
Cited by
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Rodríguez-Perálvarez, M., Luong, T. V., Andreana, L., Meyer, T., Dhillon, A. P., & Burroughs, A. K. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2513-1 · Cited by 657
Kogure, T., Lin, W.-L., Yan, I. K., Braconi, C., & Patel, T. (2011) · Hepatology · doi:10.1002/hep.24504 · Cited by 551
Cancer stem cells in the development of liver cancer
Yamashita, T., & Wang, X. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66024 · Cited by 525
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Metadata
- Authors
- Whittaker, S., Marais, R., & Zhu, A. X.
- Venue
- Oncogene
- Published
- 2010-07-19
- Volume
- 29
- Issue
- 36
- Pages
- 4989-5005
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2038625523
- Cited by
- 825
- References
- 150
- FWCI
- 43.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.